Indiana University Health University Hospital
Indianapolis, Indiana, 46202-5121, United States
NCT Number: NCT04693754
The purpose of having this database is to collect data related to endoscopic ultrasound RFA procedures performed by Indiana University EUS physicians for the treatment of tumors or adenopathy. This database is a repository database only, all information will be obtained in the electronic medical record. No additional clinical procedures will be performed outside current standard of care for endoscopic ultrasound. The patient will have already signed an informed consent for the endoscopic ultrasound. Subjects will be entered into the database for up to 10 years after the most recent procedure.
Interested in participating?
Request Info14 year and older
All sexes
Observational
Indianapolis, Indiana, 46202-5121, United States
Radiofrequency ablation (RFA) is a well-established therapeutic option for ablation of dysplastic and neoplastic tissue by the use of local thermal coagulative necrosis. Options for administration include percutaneous or a surgical approach. Percutaneous RFA is effective and safe, but it is unfeasible in cases of lesions with interposition of organs and/or vessels. For lesions such as the pancreas, surgery-assisted RFA has been described but requires general anesthesia and is associated with a substantial risk of thermal injuries to major vessels or adjacent structures.
EUS-guided RFA is a minimally invasive approach that offers high-quality real-time imaging guidance during selective ablation of benign (1-5) or malignant (6-7) pancreatic lesions. Treatment in small case series has shown to produce local necrosis with minimal adverse events. Other sites treated include the liver and metastatic adenopathy.
This database will collect data related to endoscopic ultrasound RFA procedures performed by Indiana University EUS physicians for the treatment of tumors or adenopathy. No additional clinical procedures will be performed outside current standard of care for endoscopic ultrasound. The patient's information collected will be pre-procedure identification of the adenopathy, labs, the endoscopic ultrasound(s) and post procedure follow up and care related to the adenopathy.
Patients will be contacted by phone at post-procedure 1 & 2 weeks and asked to report symptoms related to the procedure.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects 14 years of age and older Referral for the treatment of a benign or malignant tumor or adenopathy
Exclusion criteria
Time frame: Day of procedure
This data will be used for to determine the clinical impact and safety of these procedures.
Time frame: 1 week following procedure
1 week phone follow up
Time frame: 2 weeks following procedure
2 week phone follow up
Indiana University
Other
Acronym: EUS-RFA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03310632
Digestive System Diseases, Digestive System Neoplasms
Tampa, Florida, United States
View Trial DetailsNCT06400472
Adnexal Diseases, Breast Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT04239573
Digestive System Diseases, Digestive System Neoplasms
Birmingham, Alabama, United States
View Trial DetailsNCT06051695
Adenoma, Adnexal Diseases
Gilbert, Arizona, United States
View Trial Details